Metabolic abnormalities in adults with cystic fibrosis

Respirology

Volumn 15, Issue 5, 2010, Pages 823-829

  Georgiopoulou, Vasiliki V ^a   Denker, Adam ^a   Bishop, Kathy L ^a   Brown, Jason M ^a   Hirsh, Benjamin ^a   Wolfenden, Linda ^b   Sperling, Laurence ^a  

^a Section of Preventive Cardiology   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

adult; cystic fibrosis; diabetes mellitus; triglyceride

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLESTEROL; CORTICOSTEROID; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROUPS BY AGE; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFORMATION PROCESSING; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC DISORDER; NUTRITION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN; LIPID METABOLISM; LIPIDS; MALE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953852084     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01771.x     Document Type: Article

References (41)

1. Rosenstein BJ, Zeitlin PL. Cystic fibrosis. Lancet 1998 351: 277 82.
2. Cystic Fibrosis Foundation. Annual patient registry. 2006 Accessed 20 Jun 2009.] Available from URL: http://www.cff.org/LivingWithCF/QualityImprovement/ PatientRegistryReport/
3. Slieker MG, Uiterwaal CS, Sinaasappel M et al. Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands. Chest 2005 128: 2309 15.
4. Dodge JA, Lewis PA, Stanton M et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 2007 29: 522 6.
5. Marshall BC, Butler SM, Stoddard M et al. Epidemiology of cystic fibrosis-related diabetes. J. Pediatr. 2005 146: 681 7.
6. van den Berg JM, Morton AM, Kok SW et al. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J. Cyst. Fibros. 2008 7: 515 19.
7. Schlesinger DM, Holsclaw DS, Fyfe B. Generalized atherosclerosis in an adult with CF and diabetes mellitus. Pediatr. Pulmonol. 1997 16 (Suppl. 14 365A.
8. Onady GM, Farinet CL. An adult cystic fibrosis patient presenting with persistent dyspnea: case report. BMC Pulm. Med. 2006 6: 9.
9. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD et al. Deaths: final data for 2006. Natl Vital Stat Rep. 2009 57: 1 134.
10. Rosamond W, Flegal K, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 117: e25 146.
11. Sarwar N, Danesh J, Eiriksdottir G et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 115: 450 8.
12. Burdge GC, Goodale AJ, Hill CM et al. Plasma lipid concentrations in children with cystic fibrosis: the value of a high-fat diet and pancreatic supplementation. Br. J. Nutr. 1994 71: 959 64.
13. Slesinski MJ, Gloninger MF, Costantino JP et al. Lipid levels in adults with cystic fibrosis. J. Am. Diet. Assoc. 1994 94: 402 8.
14. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004 125: 1S 39S.
15. Figueroa V, Milla C, Parks EJ et al. Abnormal lipid concentrations in cystic fibrosis. Am. J. Clin. Nutr. 2002 75: 1005 11.
16. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008 300: 2142 52.
17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 1996 3: 213 19.
18. Hahalis G, Kremastinos DT, Terzis G et al. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis 2008 198: 448 57.
19. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003 26: 3160 7.
20. Moran A, Hardin D, Rodman D et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res. Clin. Pract. 1999 45: 61 73.
21. Rosenfeld M, Emerson J, Williams-Warren J et al. Defining a pulmonary exacerbation in cystic fibrosis. J. Pediatr. 2001 139: 359 65.
22. Carroll MD, Lacher DA, Sorlie PD et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005 294: 1773 81.
23. Koch C, Rainisio M, Madessani U et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr. Pulmonol. 2001 32: 343 50.
24. Tabary O, Corvol H, Boncoeur E et al. Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions. Am. J. Physiol. Lung Cell Mol. Physiol. 2006 290: L588 96.
25. Ionescu AA, Nixon LS, Luzio S et al. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002 165: 495 500.
26. Engstrom G, Hedblad B, Janzon L et al. Long-term change in cholesterol in relation to inflammation-sensitive plasma proteins: a longitudinal study. Ann. Epidemiol. 2007 17: 57 63.
27. Sammalkorpi K, Valtonen V, Kerttula Y et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988 37: 859 65.
28. Parks EJ, Hellerstein MK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am. J. Clin. Nutr. 2000 71: 412 33.
29. Daniels L, Davidson GP, Martin AJ. Comparison of the macronutrient intake of healthy controls and children with cystic fibrosis on low fat or nonrestricted fat diets. J. Pediatr. Gastroenterol. Nutr. 1987 6: 381 6.
30. Kalivianakis M, Minich DM, Bijleveld CM et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am. J. Clin. Nutr. 1999 69: 127 34.
31. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 1998 141 (Suppl. 1 S57 62.
32. Nordestgaard BG, Benn M, Schnohr P et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007 298: 299 308.
33. Brunzell JD. Clinical practice. Hypertriglyceridemia. N. Engl. J. Med. 2007 357: 1009 17.
34. Alipour A, van Oostrom AJ, Izraeljan A et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2008 28: 792 7.
35. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004 109: II2 10.
36. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am. J. Cardiol. 2002 89: 33D 38D.
37. Ciabattoni G, Davi G, Collura M et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2000 162: 1195 201.
38. Cyrus T, Tang LX, Rokach J et al. Lipid peroxidation and platelet activation in murine atherosclerosis. Circulation 2001 104: 1940 5.
39. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog. Cardiovasc. Dis. 2003 45: 293 304.
40. Constans J, Pellegrin JL, Peuchant E et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur. J. Clin. Invest. 1994 24: 416 20.
41. Laryea M, Watt KD, Molinari M et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl. 2007 13: 1109 14.